in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding it to the final 503A bulks list, citing nonclinical toxicity, an unresolved cardiac signal, and immunogenicity risk
When a masking protein in removed, activity increases
No additional somatic alterations were identified (including HER2 and EGFR ), and the proband was treated with second-line afatinib following disease progression on chemotherapy, with a partial response in the lung and stable disease for 16 months in the bone 211
In rare cases, some users may experience allergic reactions or heightened sensitivity to certain components
Cancer , 115 , 741-751, doi: Das, F., Dey, N., Bera, A., Kasinath, B